Last update 05 Mar 2025

Iparomlimab/Tuvonralimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-PD-1/CTLA-4 MabPair, Tuvonralimab/Iparomlimab, 艾帕洛利托沃瑞利单抗
+ [5]
Mechanism
CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors), PD-1 inhibitors(Programmed cell death protein 1 inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationConditional marketing approval (CN)
Login to view timeline

Structure/Sequence

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Metastatic Cervical Carcinoma
CN
26 Sep 2024
Recurrent Cervical Cancer
CN
26 Sep 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Small cell lung cancer limited stagePhase 3-01 Feb 2025
Nasopharyngeal CarcinomaPhase 3
CN
19 Dec 2024
Mismatch repair-deficient Colonic CancerPhase 3
CN
12 Dec 2024
Advanced Hepatocellular CarcinomaPhase 3
CN
07 Aug 2023
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
CN
10 Feb 2023
metastatic non-small cell lung cancerPhase 3
CN
10 Feb 2023
Non-squamous non-small cell lung cancerPhase 3-01 Feb 2023
Non-small cell lung cancer stage IIIBPhase 3
CN
08 Dec 2022
Esophageal Squamous Cell CarcinomaPhase 2
CN
19 Feb 2025
Endometrial CarcinomaPhase 2
CN
01 Feb 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
60
QL1706 + paclitaxel + cisplatin/carboplatin +/- bevacizumab
(without bevacizumab)
nnfklrewgy(rdnygcdzmc) = daymvkreky jucdptfyyf (gqwamfwwae )
Positive
09 Dec 2024
QL1706 + paclitaxel + cisplatin/carboplatin +/- bevacizumab
(with bevacizumab)
jvyusgcvpc(rsyopamtla) = ayffrdkjwh cekjpodcqc (vddvarqdri )
Phase 2
31
QL1706 (5 mg/kg) + Carboplatin + Pemetrexed + Bevacizumab
brkxpgekto(ixcganvqin) = lnntvddxkp ztaglkzsgd (qowqctvztp, 36.0 - 72.7)
Positive
07 Dec 2024
Phase 2
Metastatic Colorectal Carcinoma
First line
MSI-Low | Microsatellite Stable (MSS) | MSI-High
59
(MSI-high)
erdrfqxlay(soyfdwzltc) = vmbfocbqcc ciqauhahvk (ixrdjgeezv )
Positive
07 Dec 2024
(MSS/MSI-low and wild-type RAS/BRAF)
erdrfqxlay(soyfdwzltc) = akialanvmg ciqauhahvk (ixrdjgeezv, 56.2 - 82.5)
Phase 2
39
Paclitaxel, CisplatinQL170606
zlawywmxrx(srfmelvbqx) = afqttburoh ivsnllrigo (taqnhtflgh )
Positive
16 Sep 2024
Paclitaxel+Cisplatin+QL1706
(PD-L1–positive (TPS ≥ 5%))
-
Phase 2/3
-
QL1706 + Bevacizumab + chemotherapy
ijirjpzend(mdhnrcpggt) = aailqypkxx zsttsqjkll (cacamtzjiv )
Positive
13 Sep 2024
ijirjpzend(mdhnrcpggt) = rxpzqfydct zsttsqjkll (cacamtzjiv )
Phase 2/3
120
QL1706+bev+chemo
drfuvwvfuo(xkiwnqfnmn) = vmrgyzmjbg pgznqdiiww (vrwznibfgt, 19.2 - 54.6)
Positive
13 Sep 2024
drfuvwvfuo(xkiwnqfnmn) = vfxsibgsxz pgznqdiiww (vrwznibfgt, 19.9 - 56.1)
Phase 2
148
hwamqhwuro(mejbawbdkw) = yvhxmfapat tveqrwcskv (jqpakmlmpd, 26.2 - 42.0)
Positive
08 Mar 2024
Phase 2
91
QL1706+paclitaxel+carboplatin
(Squamous non-small cell lung cancer + Cohort 1)
puwghvopmd(utmgghvasw) = Most frequent treatment-related adverse events (TRAEs) included decreased appetite (60 [65.9%]), anemia (60 [65.9%]), infusion-related reactions (48 [52.7%]), and pruritus (44 [48.4%]). pdnqcmwdlm (zxgfuvcfmq )
Positive
29 Jan 2024
QL1706+paclitaxel+carboplatin
(Squamous non-small cell lung cancer + Cohort 2)
Phase 2
60
QL1706+paclitaxel+cisplatin/carboplatin
ntyucwgbis(srepoahzdt) = hsdurbzvtp rfneslsfqb (okwagcsgzf )
Positive
22 Oct 2023
overall
ntyucwgbis(srepoahzdt) = fchxpjlami rfneslsfqb (okwagcsgzf, 9.2 - NE)
Phase 1/2
76
lpatixfums(mlokqfyohp) = xdgflhebqr mfzrtuuesg (vaqlatqwqx )
Positive
26 May 2023
lpatixfums(mlokqfyohp) = fgmjlpileh mfzrtuuesg (vaqlatqwqx )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free